All In Biotech

NDA 050600 · Pfizer

Cleocin T

Clindamycin Phosphate · Topical

Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1989

May 31, 1989

Approved uses

1

Original approval plus efficacy supplements

Registered trials

274

66 Phase 3, 28 recruiting

FAERS reports

3,969

2,541 serious, 292 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 17, 2026.

INDICATIONS AND USAGE CLEOCIN T Topical Solution, CLEOCIN T Topical Gel and CLEOCIN T Topical Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate (see CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS ).

Mechanism: Mechanism of Action The mechanism of action of clindamycin in treating acne vulgaris is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 31, 1989 Original approval · Type 3 - New Dosage Form
1 products under this application
  • CLEOCIN T · CLINDAMYCIN PHOSPHATE EQ 1% BASE · LOTION, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective386
  • rash285
  • off label use258
  • drug hypersensitivity240
  • nausea227
  • diarrhoea226
  • fatigue211
  • pruritus186
  • pain178
  • condition aggravated151
  • headache136
  • dyspnoea135

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200422
200563
200662
200715
200830
200948
201093
201183
2012115
2013109
2014117
2015147
2016277
2017200
2018253
2019298
2020227
2021217
2022312
2023325
2024317
2025345
2026293

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cleocin T (Clindamycin Phosphate)

2024 spending

$7K

Beneficiaries

27

66 claims

Per beneficiary

$266

$1.79 per unit

View as table
YearSpending
2020$13,463
2021$12,291
2022$14,706
2023$9,762
2024$7,185

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,207 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.